PubMed:17255138 / 0-309 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"3881","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"3882","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"3883","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3884","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3885","span":{"begin":227,"end":243},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"db_id","subj":"3881","obj":"MESH:D052246"},{"id":"A2","pred":"db_id","subj":"3882","obj":"MESH:D000894"},{"id":"A3","pred":"db_id","subj":"3883","obj":"MESH:D009203"},{"id":"A4","pred":"db_id","subj":"3884","obj":"MESH:D009203"},{"id":"A5","pred":"db_id","subj":"3885","obj":"MESH:D052246"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T2","span":{"begin":134,"end":163},"obj":"Sentence"},{"id":"T3","span":{"begin":164,"end":175},"obj":"Sentence"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004781"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005068"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":28,"end":38},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":217,"end":220},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":233,"end":243},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":279,"end":281},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":28,"end":38},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":233,"end":243},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D009203"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004781"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0004781"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D009203"},{"id":"A2","pred":"ID:","subj":"T2","obj":"DISEASE"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"D009203"},{"id":"A2","pred":"#label","subj":"T2","obj":"DISEASE"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":217,"end":220},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":227,"end":243},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A2","pred":"ID:","subj":"T2","obj":"ChemicalEntity"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":217,"end":220},"obj":"OrganismTaxon"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"LitCoin-training-merged","denotations":[{"id":"T4","span":{"begin":227,"end":243},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":217,"end":220},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"T16034","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T13836","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T47431","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3005","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T76475","span":{"begin":217,"end":220},"obj":"OrganismTaxon"}],"attributes":[{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A2","pred":"ID:","subj":"T2","obj":"ChemicalEntity"},{"id":"A1","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A4721","pred":"#label","subj":"T47431","obj":"DISEASE"},{"id":"A83692","pred":"#label","subj":"T3005","obj":"D009203"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"HP_0001658"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-"}